Debiopharm Research & Manufacturing
在场
Debiopharm Research & Manufacturing 的所有者是 Debiopharm Group.
Debiopharm Group 拥有 3家子公司，其中包括 Après-demain、Debiopharm International 和 Debiopharm Research & Manufacturing。
他们在：
高管
查看带有其 9 名主要高管的组织结构图
Debiopharm Research & Manufacturing 搜索最多的简介
- Cédric Sager, Chief Executive Officer
- Liem Vu Thanh, Quality Assurance Director
- Olivier Imboden, Administration and Human Resources Director
创建提醒
跟踪 Debiopharm Research & Manufacturing 的高管变动
药店
Debiopharm Group 拥有 1,842 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- BeiGene将改名为BeOne Medicines。 (公布2024十一月15号).
- GlycoMimetics and Crescent Biopharma have announced they will merge (公布2024十一月15号)..
- Grace Therapeutics将在Oct 25, 2024将其名称改为Grace Therapeutics。 (公布2024十月27号).
药店 行业的其他推荐联系人
消息
Debiopharm Research & Manufacturing 的最新新闻稿
- Debiopharm and WhiteLab Genomics announce a collaboration to advance drug target and design in Oncology - Debiopharm
- Debiopharm to Showcase Research Results of Their First-In-Class Anti-Staphylococcal Program at IDWeek 2024 in Los Angeles - Debiopharm
- Debiopharm Recognizes Groundbreaking Japanese Cancer Research During the 83rd Annual Meeting of the Japanese Cancer Association - Debiopharm
- Debiopharm & WhiteLab Genomics Announce A Strategic Partnership to Advance Drug Target and Design in Oncology - Debiopharm
- First Patients Dosed in Debiopharm's Phase III Trial (LIBELULA) Investigating Debio 4326, A 12-Month Triptorelin Formulation for Children with Central Precocious Puberty - Debiopharm
- Press Releases - Debiopharm
- ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-Based Radiopharmaceutical Programs Targeting Solid Tumors - Debiopharm
- Debiopharm pose la première pierre de son nouveau bâtiment pouvant accueillir jusqu'à 300 collaborateurs tout en sortant des énergies fossilles pour une exploitation neutre en CO2 - Debiopharm
- Debiopharm Underlines Commitment to Eradicating Antimicrobial Resistance by Sponsoring the 8th Annual World AMR Conference - Debiopharm
- Le challenge qualité de vie du patient tient les 5 finalistes de sa 9ème édition. Chaque projet reçoit la récompense de CHF 5’000 et dispose de 4 mois pour développer son idée en prototype - Debiopharm
- View more press releases Close
通过电子邮件
